Você procurou por: kardiovaskularnih (Esloveno - Inglês)

preprečevanje kardiovaskularnih bolezni
each daily dose of atorvastatin is given all at once and may be given at any time of day with or without food.

ocenjevanje kardiovaskularnih (kv) dogodkov
evaluation of cardiovascular (cv) events

poročila o mace v študiji kardiovaskularnih izidov
mace reported in cardiovascular outcomes study

pri živalih atosiban ni imel kardiovaskularnih učinkov.
in animals atosiban did not exhibit cardiovascular effects.

kardiovaskularnih dogodkov, ki so odvisni od odmerka,
increased risk of serious cv events,

v primeru hudih kardiovaskularnih obolenj moramo biti previdni.
in case of severe cardiovascular disease, care should be taken.

aklidinijev bromid in tveganja izbranih kardiovaskularnih opazovanih dogodkov.
and the risk of selected cardiovascular endpoints.

primarni kombinirani dogodki miokardni infarkt smrt zaradi kardiovaskularnih vzrokov
n=4,645

za preprečevanje kardiovaskularnih težav je priporočeni odmerek 80 mg enkrat dnevno.
for the prevention of cardiovascular problems, the recommended dose is 80 mg once a day.

opis in upravljanje venskih in arterijskih trombemboličnih dogodkov kardiovaskularnih dogodkov in periferne nevropatije
description and management of venous and arterial thromboembolic events, cardiovascular events, and peripheral neuropathy

delež kardiovaskularnih trombotičnih dogodkov se pri uporabi etorikoksiba in diklofenaka ni pomembneje razlikoval.
there was no significant difference between etoricoxib and diclofenac in the rate of cardiovascular thrombotic events.

zmanjševanje tveganja kardiovaskularnih dogodkov pri bolnikih s stabilno koronarno arterijsko boleznijo «.
reduction of risk of cardiovascular events in patients with stable coronary artery disease”.

poleg zgoraj navedenih kriterijev je za presojanje bolnikovih kardiovaskularnih funkcij potrebno klinično mnenje.
in addition to the above criteria, clinician judgement must be exercised in the evaluation of the patient’s cardiovascular functions.

po epidemioloških izsledkih je večja incidenca kardiovaskularnih pojavov povezana z določenimi pokazatelji, npr.:
according to epidemiological findings, a higher incidence of cardiovascular events has been associated with certain indicators, for instance: − age − elevated heart rate or blood pressure − persistent or recurrent ischemic cardiac pain − marked ecg changes (in particular st-segment abnormalities) − raised cardiac enzymes or markers (e. g.

pri kuncih, ki so dobivali etorikoksib, so opazili majhno od odmerka neodvisno pojavnost kardiovaskularnih malformacij.
a non-dose-related low incidence of cardiovascular malformations was observed in etoricoxib-treated rabbits.

guidant je podjetje s sedežem v zda, ki je dejavno na področju načrtovanja in razvoja kardiovaskularnih medicinskih proizvodov.
guidant is a company incorporated in the united states of america (usa) that is active in the design and development of cardiovascular medical products.

kohortna študija varnosti zdravila po pridobitvi dovoljenja za promet za inhaliran aklidinijev bromid in tveganja izbranih kardiovaskularnih opazovanih dogodkov.
post-authorisation safety (pas) cohort study of inhaled aclidinium bromide and the risk of selected cardiovascular endpoints.

ker selektivni zaviralci cox-2 nimajo antiagregacijskega delovanja, niso nadomestilo za acetilsalicilno kislino v profilaksi kardiovaskularnih trombemboličnih bolezni.
cox-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effect.

selektivni zaviralci cox- 2 ne vplivajo na antitrombocitno delovanje, zato niso nadomestilo za acetilsalicilno kislino v profilaksi kardiovaskularnih trombembolicnih bolezni.
cox-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular

te reakcije se lahko pokažejo v obliki kardiovaskularnih, respiratornih ali kožnih reakcij (glejte poglavje 4. 8).
 hypersensitivity allergoid and other idiosyncratic reactions may occur with all contrast media for intravenous application, also with gadoversetamide, which could become manifest in form of cardiovascular, respiratory and skin reactions (see section 4.8).